Immune transcriptome and antibody response in adult-onset Still's disease with mild flare following administration of mRNA vaccine BNT162b2

Rheumatology (Oxford). 2022 Oct 6;61(10):e305-e307. doi: 10.1093/rheumatology/keac281.

Authors

Ludwig Knabl¹, Hye Kyung Lee², Mary Walter³, Priscilla A Furth⁴, Lothar Hennighausen²

Affiliations

¹ TyrolPath, Obrist-Brunhuber GmbH, Hauptplatz 4, Zams, Austria.
² National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health.
³ Clinical Core, National Institute of Diabetes, Digestive and Kidney Diseases, Bethesda, MD.
⁴ Departments of Oncology & Medicine, Georgetown University, Washington DC, USA.

No abstract available

Publication types

Research Support, N.I.H., Intramural

MeSH terms

Adult
Antibody Formation
BNT162 Vaccine
Humans
Still's Disease, Adult-Onset*
Transcriptome
Vaccines, Synthetic
mRNA Vaccines

Substances

Vaccines, Synthetic
mRNA Vaccines
BNT162 Vaccine